Screener
Cogent Biosciences, Inc. COGT Total Current Assets
Total Current Assets at other companies
Other financials
Where this comes from
Reported directly by Cogent Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AssetsCurrent.
The source filing: Cogent Biosciences, Inc.’s 10-Q, filed May 5, 2026.
- Filed
- May 5, 2026, 8:21 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-205170
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Cash and cash equivalents | $241,208 | $312,012 |
| Short-term marketable securities | 625,170 | 588,753 |
| Prepaid expenses and other current assets | 11,425 | 9,590 |
| Total current assets | 877,803 | 910,355 |
| Operating lease, right-of-use assets | 17,549 | 18,078 |
| Property and equipment, net | 5,298 | 5,457 |
| Restricted cash | 416 | 416 |
| Other assets | 1,940 | 3,301 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Cogent Biosciences, Inc.'s total current assets?
- Cogent Biosciences, Inc. (COGT) reported total current assets of $877.8M in Q1 2026.
- How has Cogent Biosciences, Inc.'s total current assets changed year-over-year?
- Cogent Biosciences, Inc.'s total current assets increased by 247.1% year-over-year, from $252.88M to $877.8M.
- What is the long-term trend for Cogent Biosciences, Inc.'s total current assets?
- Over 5 years (2020 to 2025), Cogent Biosciences, Inc.'s total current assets has grown at a 30.0% compound annual growth rate (CAGR), from $244.91M to $910.36M.
- What does total current assets mean?
- The sum of all assets expected to be converted to cash or consumed within one year — cash, receivables, inventory, and prepaid expenses.
Ask your AI about Cogent Biosciences, Inc.'s total current assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude